Polaris Group (TPE:6550)
Taiwan · Delayed Price · Currency is TWD 30.45
+0.45 (1.50%)
Nov 25, 2025, 12:25 PM CST
Polaris Group Revenue
Polaris Group had revenue of 17.75M TWD in the quarter ending September 30, 2025, with 62.33% growth. This brings the company's revenue in the last twelve months to 70.83M, down -6.38% year-over-year. In the year 2024, Polaris Group had annual revenue of 107.00M with 1,330.29% growth.
Revenue (ttm)
70.83M
Revenue Growth
-6.38%
P/S Ratio
326.33
Revenue / Employee
429.27K
Employees
165
Market Cap
23.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107.00M | 99.52M | 1,330.29% |
| Dec 31, 2023 | 7.48M | 1.04M | 16.18% |
| Dec 31, 2022 | 6.44M | -8.60M | -57.19% |
| Dec 31, 2021 | 15.04M | 5.63M | 59.84% |
| Dec 31, 2020 | 9.41M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Pegavision | 6.90B |
| Sunmax Biotechnology | 2.00B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 42.59M |